Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Recruiting

Phase 1

Phase 2

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT02315326

Conditions

Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)

Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ibrutinib

HD- Methotrexate (MTX)

Rituximab + HD- Methotrexate (MTX)

procarbazine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information